Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prospera I-125
- Development stage
- Unknown
- Lead developer
- Brachytherapy Services
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Interstitial
01
Overview
Prospera I-125 (Model MED3631-A/M) is a brachytherapy seed device developed by Brachytherapy Services, Inc. It consists of sealed radioactive seeds containing Iodine-125 (I-125), a radioisotope that emits low-energy gamma radiation. These seeds are designed for interstitial implantation directly into cancerous tissue, providing localized radiation therapy while minimizing exposure to surrounding healthy organs. It is primarily used for the treatment of localized tumors, such as prostate cancer, where internal radiation therapy is indicated.
- Brand names
- Prospera I-125
- Other names
- Iodine-125Iodine125Iodine 125I-125I125I 125Iodine-125 brachytherapy seedIodine125 brachytherapy seedIodine 125 brachytherapy seed
02
Targets
DNA
Beyond the preview
Go deeper on Prospera I-125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prospera I-125.